Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cell exosomes (RIGLD)
- Development stage
- Unknown
- Lead developer
- Research Institute for Gastroenterology and Liver Diseases
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is an investigational cell-free biologic therapy consisting of exosomes derived from umbilical cord-derived mesenchymal stem cells (UC-MSC-derived exosomes). Developed by the Research Institute for Gastroenterology and Liver Diseases (RIGLD) in Iran, it is currently being evaluated in a Phase IIa clinical trial (NCT05871463) for the treatment of decompensated liver cirrhosis. The therapy aims to provide a safer, cell-free alternative to direct MSC transplantation by utilizing nano-sized extracellular vesicles secreted by stem cells. Its biological mechanism involves paracrine signaling that targets liver fibrosis by inhibiting the TGF-β/Smad signaling pathway, reducing collagen deposition, modulating hepatic stellate cell activity, and reversing epithelial-to-mesenchymal transition (EMT).
- Other names
- UC-MSC-derived exosomesMSC-derived exosomesMesenchymal Stem Cell-Exosomes
02
Targets
SMAD2 (Mothers against decapentaplegic homolog 2)SMAD7 (Mothers against decapentaplegic homolog 7)TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cell exosomes (RIGLD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cell exosomes (RIGLD).